Abstract: Many different plant-based systems have been used to produce recombinant pharmaceutical proteins but only a small number have made the leap from an experimental platform to a viable commercial process. This reflects a combination of factors, principally the technical issues that must be addressed to achieve competitive performance, the economic principles that need to be satisfied to ensure manufacturing processes are financially viable and sustainable, and the regulatory demands that must be met to ensure that pharmaceuticals manufactured in plants are safe, efficacious and meet the quality standards demanded by the regulators. With the recent approval of the first plant-derived recombinant pharmaceutical protein designated for human use, we are now entering a new era in which plants not only meet all the demands of a commercial pharmaceutical manufacturing process but also provide unique benefits that allow the displacement of established platform technologies in niche markets. In this article, we consider the commercial aspects of molecular farming, specifically those required to make plants more competitive and attractive to industry.
THE PROMISE OF MOLECULAR FARMING
Plants have been used experimentally to produce recombinant human pharmaceutical proteins since 1989 but the first commercial product was not launched until 2012 [1] [2] [3] . During the long interval between concept and realization, those working in the field of molecular farming labored to bridge the gap between the scientific principle and commercial reality, faced on one hand with a huge literature of promising scientific data and on the other with skepticism from the industry, from the regulators and from the agencies tasked with funding translational research.
The enthusiasm for molecular farming in the research community reflected several predicted and perceived advantages of plants compared to established fermenter-based platforms. These included (i) the low cost of establishing and maintaining pharmaceutical crops compared to building and running the infrastructure for industrial-scale fermentation; (ii) the scalability of plants compared to fermenters; and (iii) the favorable safety profile, given that plants do not support the replication of mammalian pathogens and many crops fall under the 'generally regarded as safe' (GRAS) definition based on generations of experience from producers and consumers [4] . These factors led to a large number of proof-of-principle studies involving a diverse and eclectic range of different plant species and platforms [5] and also to the founding of numerous start-up companies focusing on unique platform technologies [6] . But very few of those companies are still in business today and only a small number of platforms have proven to be commercially viable. Molecular farming can be described as a disruptive technology because it seeks to take a market share from established technologies not by incremental improvements but by changing the game plan. On paper, the proposal looks good. It should be possible to displace a competitor by offering a cheaper product, a better-quality product or a more versatile product, e.g. faster production or greater production capacity. Molecular farming offers all three, so why has the uptake of the technology been so slow?
*Address correspondence to this author at the Fraunhofer IME, Forckenbeckstrasse 6, 52074 Aachen, Germany; Tel/Fax: +49 241 6085 11020; E-mail: rainer.fischer@molbiotech.rwth-aachen. de No single event was responsible for bursting the original molecular farming bubble in the 1990s, but a combination of technical, economic, social and regulatory issues led to the re-evaluation of its potential and a re-positioning of its relationship with the biopharmaceutical industry in the 2000s. One of the great strengths of molecular farming is its diversity, but in the early days this was also a significant weakness. The biopharmaceutical industry has always focused on a small number of standardized platforms and has invested its resources to maximize their performance, focusing on the platform rather than the product. In contrast, molecular farming was a fragmented discipline, offering diverse platforms that could be selected to match the requirements of different recombinant proteins. But this also meant there was no driving force to establish molecular farming as a single, competitive platform, and therefore no effort to meet industry requirements for high yields, standardized procedures and regulatory compliance [3] . Molecular farming is now more firmly established because it has focused on a small number of platforms that meet industry demands. It has concentrated on improving the performance of these platforms so that they become more competitive, defining a clear regulatory pathway and exceeding the capabilities of traditional platform technologies for a small number of niche products, as discussed in greater detail by Paul et al. in this issue. In this article, we focus on the more general barriers to the commercialization of molecular farming, including aspects such as downstream processing, quality control and regulatory compliance. A timeline of major events in the history of molecular farming is shown in Fig. 1. 
ECONOMIC BARRIERS TO COMMERCIALIZATION
The pioneers of molecular farming considered the benefits of plants as an upstream production platform but few looked at the economics of the entire production process, and particularly the costs of downstream processing (DSP). These can account for up to 80% of the total production costs and the most expensive steps are often product-specific, based on the chromatography media required to isolate particular proteins [7, 8] .
Surprisingly, the first comprehensive studies considering full production costs were not published until nearly a decade after the first human proteins were produced in plants. Furthermore, these were carried out in the context of manufacturing nonpharmaceutical proteins envisaged as technical reagents, so the additional costs of virus clearance/inactivation and compliance with good manufacturing practice (GMP) were not considered. The initial studies were carried out by researchers working at Prodigene Inc. who were developing maize seeds as a commercial platform [9] . The lead product was the egg protein avidin, which they produced in maize with a yield of 230 mg per kg of transgenic seed and whose structure and activity were almost identical to native avidin from hens' eggs. The key findings were that the protein remained stable when the seeds were stored at 10°C, it was not degraded by commercial processing operations (dry milling, fractionation and hexane extraction) and as such could be produced commercially at a price low enough to compete with egg-derived avidin [10] . This was an important principle because it established that products manufactured in maize could compete with alternatives even if the source was not particularly scarce. Similarly, the enzyme -glucuronidase could be produced in maize with a yield of approximately 80 mg per kg of dry seeds, it was similar in structure and activity to the native enzyme, was stable in seeds stored at 10°C, was stable during normal processing operations and was economically competitive with the native enzyme produced in E. coli [9, 11] . These and other products were marketed by SigmaAldrich Fine Chemicals (St Louis, MI) before Prodigene Inc. ceased trading after fines levied for a breach of environmental regulations.
Importantly, before their demise, Prodigene Inc. were also interested in the production of pharmaceutical proteins for human use and had developed a number of maize lines expressing vaccine antigens and antibodies [12] [13] [14] . A significant effort to determine the full economic benefits of plant-derived vaccines was later undertaken by Charles Arntzen and colleagues under the Production of Vaccines from Applied Crop Sciences (PROVACS) initiative at Arizona State University, concluding that the use of plants would save 62% of effective costs (i.e. including distribution) in developed countries and up to 90% in developing counties (http: //www.iphandbook.org/handbook/ch17/p23/).
For both pharmaceutical and non-pharmaceutical products, Prodigene Inc. placed a great deal of emphasis on the development of cost-effective downstream processing because the commercial viability of a product depends ultimately not on the yield in planta, but on the yield and quality after purification [15] [16] [17] . Many of the principles now applied to DSP in molecular farming were developed in these early studies including the importance of tailoring the first processing steps to account for the peculiarities of different production hosts (e.g. the removal of cellulose fibers, oils and other byproducts from certain crops) and dealing with specific interfering compounds found in plants. For example, the extraction of recombinant aprotinin from maize seeds was initially hampered by the copurification of an endogenous maize trypsin inhibitor, a challenge that was eventually solved by modifying the downstream processing steps to include acid extraction followed by the heat-denaturing of host proteins [18] [19] [20] . This example also shows why the selection of a production host should also take into account the economic impact of DSP, because the same recombinant aprotinin was later produced in tobacco, which does not express an endogenous trypsin inhibitor. Whereas the maximum purity that could be achieved in maize was 75%, in tobacco the purity of the processed recombinant aprotinin was 99% [21] .
Commercial molecular farming based on seeds has also been established by other companies, which have developed economically-viable production processes by ensuring that downstream processing is cost-effective. For example, Ventria Bioscience (Fort Collins, USA) produces several vaccines and proteins such as human albumin, transferrin, lactoferrin and lysozyme in rice seeds. The purification of recombinant lysozyme is inhibited by the presence of phytic acid in the seed because this has a strong negative charge and competes with the cationic exchange resin to bind the recombinant protein. Downstream processing therefore involves unique steps to remove the phytic acid, such as acid hydrolysis and precipitation [22, 23] . Further companies have established economic models for molecular farming that do not yet include pharmaceutical products, but which appear to be 'primed' in readiness for a strategic decision to enter the market. For example, ORF Genetics produces human growth hormone and cytokines in barley seeds. These products are currently approved for diagnostic use, academic and private research, and in the case of growth hormone as a cosmetic additive (distributed by Sif Cosmetics, Iceland). Similarly, Kentucky BioProcessing (Owensboro, KT) is currently producing aprotinin for research purposes in tobacco and has a GMP manufacturing facility which could be used to develop a pharmaceutical product, but as yet no clinical-grade aprotinin is being produced. First specific molecular farming company
TECHNICAL BARRIERS TO COMMERCIALIZATION
The first major technical hurdle faced by the pioneers of molecular farming was the low yields that were initially achieved in transgenic plants compared to established platforms. In the context of developing a commercially viable process, the intrinsic yield (i.e. the accumulation of product per unit biomass) is not as important as the overall economy of the process (i.e. if the low yield can be offset by greater scalability and larger-scale production is still cheaper overall than a fermenter then it is economically viable) but this becomes increasingly untenable when downstream processing costs are considered. Whereas upstream production benefits from the economy of scale (i.e. it does not cost significantly more to double the number of plants producing a given protein whereas doubling the capacity of a fermenter facility can be prohibitively expensive) the costs of downstream processing are more linear (i.e. more biomass equals more contaminants to remove equals more filter cassettes and chromatography resins, making the process overall much less economical). Therefore, despite the advantages of scalability there is still a huge impetus to increase the intrinsic yields of recombinant proteins in plants and to increase the concentration of recombinant protein in the biomass.
There are many strategies now available to increase the yields of recombinant proteins in plants, and these are considered in detail by Twyman et al. in this issue. One important aspect to consider in the context of pharmaceutical proteins is that strategies that increase yields by changing the protein structure (e.g. by adding targeting or stabilizing sequences) impose a greater regulatory burden and require additional downstream processing steps to remove the extraneous sequences, potentially adding to the costs in a way that offsets the benefits of boosting the yields. Since many of the problems with low yields are caused by interference with the expression of integrated transgenes, there is now considerable interest in transient expression systems based on Agrobacterium tumefaciens and/or engineered plant viruses that avoid transgene integration and achieve a shorter production cycle [24] [25] [26] [27] [28] . In some crops it is also possible to increase yields by introducing DNA into the plastid genome [29] .
Glycosylation is another important technical aspect of molecular farming with an impact on the quality attributes of the product because glycan structures can affect the stability, targeting, immunogenicity, pharmacokinetic properties and biological activity of a protein. The mechanism of N-glycosylation in plants is similar to that in humans until the nascent N-glycan reaches the Golgi apparatus, whereupon it is decorated with species-dependent oligosaccharide structures including 1,2-xylose and core 1,3-fucose residues (in plants but not in mammals) and 1,4-galactose and sialic acid residues (in mammals but not plants) [30] . Although plant glycans on recombinant pharmaceutical proteins have yet to be proven immunogenic or harmful in humans, there has been a significant effort to either prevent the addition of plant glycans or humanize the glycosylation pathway, e.g. by retrieving proteins to the ER before they are exposed to Golgi-resident enzymes or genetically modifying plants to eliminate plant-type glycosylases and introduce human ones [31] [32] [33] [34] . Nevertheless, several companies developing recombinant pharmaceutical proteins derived from plants have demonstrated that the glycan profiles generated in plants can improve the performance of their products -biobetters rather than biosimilarsas we discuss in more detail below.
REGULATORY BARRIERS TO COMMERCIALIZATION
Although significant progress was made in the 1990s to develop viable economic models for non-pharmaceutical molecular farming, the commercial production of pharmaceutical proteins was prevented until recently by the absence of a coherent regulatory framework. Draft legislation jointly developed by the US Department of Agriculture (USDA) and the Food and Drugs Administration (FDA) was flexible in terms of the platforms covered and the interpretation of GMP guidelines [35] . However, the European Medicines Agency (formerly EMEA, now EMA) based its draft guidelines heavily on the existing model for mammalian cells, which were next to useless when applied to plants because they relied on incompatible concepts such as cell banking and batch-tobatch consistency based on clonal identity [36, 37] . Some stakeholders therefore pursued the use of cultivated plant cells for the production of biopharmaceuticals (see Schillberg et al., this issue). This decision was based on the rationale that plant cells can be handled in much the same way as mammalian cells and can be regulated under the same guidelines, but the switch from animals to plants nevertheless represents an incremental advance towards the acceptance of molecular farming as a commercially viable process for pharmaceutical manufacturing. The CONCERT TM production platform based on tobacco BY-2 cells is one example of this approach, and led to the development of a poultry vaccine by Dow AgroSciences which was approved by the USDA but has not been commercialized for strategic reasons (see Schillberg et al., this issue). The Israeli company Protalix BioTherapeutics followed the same route to develop the ProCellEx platform based on carrot cells, which is used to produce biopharmaceuticals for human use [38, 39] . In both cases, the systems are analogous to mammalian cells in both conceptual and practical terms and they comply with FDA and EMA GMP guidelines, and this means that other products manufactured using plant cell/tissue platforms are now close to market ( [3, 40, 41] , and see Schillberg et al., this issue).
Plant cells suffer from many of the same limitations as animal cells in terms of their reliance on fermenter infrastructure which means they have a low capacity and scalability. To pursue the advantages of whole plants it was necessary to develop new regulations integrating the unique properties of plants and the diverse characteristics of different molecular farming platforms. Here again there is a gulf between the regulatory practices in Europe and the US. Whereas the FDA guidelines have the flexibility to accept all plant-based production platforms [35] , the updated EMA guidelines that came into effect in 2009 consider only stable transgenic plants and do not acknowledge the existence of transient expression platforms [42] . For this reason, GMP manufacturing based on transient expression in leafy crops such as tobacco and alfalfa is flourishing in the US but is currently effectively banned in Europe because it has no regulatory 'home' and the only GMP-compliant platforms in Europe are based on stably-transformed transgenic plants [43, 44] . Importantly, a new Clinical Trials Directive was published in the EU at the same time as the updated guidelines for molecular farming, stipulating that all biopharmaceutical products intended for phase I trials must be manufactured according to GMP. The importance of GMP compliance is therefore now relevant from the very beginning of clinical development. Some plant-derived pharmaceutical products have been tested in phase I trials without the need for GMP manufacture but all products entering clinical development now and in the future must comply with GMP before human trials can be authorized. The successful development of GMP guidelines for transgenic tobacco is arguably the most important breakthrough in the commercial development of molecular farming, because this now provides the accepted pathway to follow for the manufacture of pharmaceutical proteins in different whole plants [3] .
THE EXPLOITATION OF NICHE MARKETS
With the economic, technical and regulatory barriers to commercial molecular farming now all but dismantled, the final stage for commercial development is to establish positions of strength in niche markets. This is important because plants now represent one of several competing platforms, but they are the least secure and could easily lose their market share either due to technological and/or economic improvements in competing platforms or through a failure to maintain a competitive advantage through unforeseen technological or regulatory challenges that might be described as 'teething problems'.
On this basis, all the plant-derived pharmaceutical products that are already marketed or are close to commercialization have unique benefits conferred by the particular and idiosyncratic properties of the production host, which as discussed above are motivated by the nature of the product and not by the nature of the platform (see also Paul et al., this issue). The ability of molecular farming to conquer diverse niche markets thus reflects the diversity of plant-based production platforms that confer a degree of adaptability and flexibility that cannot be matched by CHO cells or microbes.
The Benefits of Regulated Glycosylation in Plants
As discussed above, there has been an immense effort to eliminate plant glycans because of their perceived regulatory burden, and to introduce human glycosylation patterns in plants. However, several products are now in development which embrace the potential of glycosylation in plants, and the only approved plant-derived pharmaceutical protein at the time of writing has a niche market mainly because of its superior glycan profile. Elelyso (generic name taliglucerase alfa) is a recombinant form of glucocerebrosidase produced by Protalix BioTherapeutics using their ProCellEx platform and marketed in concert with Pfizer Inc. Glucocerebrosidase is a glycoprotein whose activity and uptake by macrophages depends on terminal mannose residues that are preserved when it is produced in carrot cells [45] . In contrast, the current market leader Cerezyme (imiglucerase) produced by Genzyme Corp. is manufactured in CHO cells and has terminal sialic acid residues that need to be enzymatically removed in vitro to expose the critical mannose residues. For this reason the plant-derived product is advantageous because downstream processing is more cost effective. Similarly, Synthon BV (which has just purchased the LEX technology based on the aquatic plant Lemna minor from Biolex Therapeutics) produces "glyco-optimized" proteins that have distinct glycan profiles and thus better pharmacokinetic properties compared to their counterparts derived from mammalian cells. The lead product is a therapeutic CD20-specific antibody indicated for non-Hodgkin lymphoma which has a tenfold higher affinity for its receptor and a 20-fold greater antibody dependent cellular cytotoxicity (ADCC) against tumor cells [46] .
The Benefits of Rapid Scalability
An early product candidate to emerge as a molecular farming front runner was an anti-idiotype vaccine for non-Hodgkin lymphoma, which was originally produced using virus vectors in tobacco [47] and is now being produced using the high-yielding magnICON platform [48] . The production of idiotype vaccines, which are personalized for individual-specific B-cell lymphomas, is technically feasible using mammalian cells but economically and practically challenging because each individual would require a dedicated fermenter facility and would need to endure the long development time required to produce mammalian cell lines expressing the vaccine at sufficient levels. The ability to rapidly produce these vaccines in plants by transient expression provided a solution to both the cost implications and the development times, since large amounts of recombinant protein can be recovered from plants within a matter of days [49, 50] . The advantage of rapid production in concert with the rapid scalability of crops such as tobacco and alfalfa provides another niche market for transient expression in plants. The most effective way to respond to an emerging pandemic or bioterrorist threat is to deploy strategic vaccines, but traditional production methods take a long time to scale up and would not be able to cope with a rapidly-spreading contagious disease such as influenza. Models suggest that it would take up to 6 months to reach production targets for a pandemic influenza vaccine in western countries using egg-based production, but that the disease would peak within 3 months [51, 52] . However, several organizations now offer GMP manufacturing based on transient expression in tobacco, or its close relative Nicotiana benthamiana, including Kentucky BioProcessing (Owensboro, KY), Icon Genetics (Halle, Germany), Fraunhofer CMB (Newark, DE) and Medicago (Quebec, Canada). An additional facility is being constructed by Texas A&M University (College Station, TX) and G-Con, LCC. Transient systems produce large amounts of recombinant protein rapidly (milligram quantities per plant within a few days) and can be scaled up quickly, currently providing the only reliable platform for rapid response situations. Medicago Inc. found that their alfalfa-based transient expression system could provide batches of virus-like particles for vaccination against H1N1 and H5N1 strains of influenza within three weeks of receiving the hemagglutinin and neuraminidase gene sequences [52, 53] . The Fraunhofer Centre for Molecular Biotechnology (Newark, US) has also produced vaccines in a few weeks from sequence to product by transient expression in tobacco using their iBioLaunch platform, including influenza hemagglutinin subunits from strains H3N2 [54] , H5N1 and H1N1 [55] at yields between 50 and 200 mg of recombinant protein per kg of fresh leaves.
The Benefits of Large-scale Production for Commodity Pharmaceuticals
Whereas some recombinant proteins are required in large amounts rapidly, others are required in immense amounts continuously and plants again provide a solution that cannot be met by other production platforms. An example of such as product is the HIV-neutralizing antibody 2G12, which can be used as part of a microbicidal cocktail to prevent HIV infections when applied before sexual intercourse [56] . Effective protection requires the repetitive application of milligram quantities of antibody. This would be prohibitively expensive if produced using conventional fermenter technology and the demand for such an antibody would rapidly outstrip the entire global capacity for GMP production if the product were to be sold as a conventional pharmaceutical product in the developed world, but the target population is predominantly in subSaharan Africa and includes the world's poorest people. The only way to meet this demand is to grow pharmaceutical crops on a vast scale using local infrastructure, a concept developed in the EU Pharma-Planta project which resulted in the first phase I clinical trial of a plant-derived pharmaceutical protein from a publicallyfunded research project [2] . The driving force in this scenario is scale not speed, and the best platform is transgenic plants, which can be grown on a massive scale without skilled labor allowing the production and processing of 200-1000 kg batches of leaves at a fraction of the cost of fermenters. Functional HIV-neutralizing antibodies have been produced in tobacco for clinical trials (Fig. 2) and also in maize seeds as a competitive platform for the development of novel microbicides intended for deployment in developing countries [57] [58] [59] .
The Benefits of Edible Plant Organs
The final niche market we consider is the edible plant organ (leaves, seeds and fruits) which can be used to produce oral vaccines and oral prophylactic antibodies. The administration of oral vaccines induces an immune response via gut-associated lymphoid tissues, which has been effective in challenge studies with many pathogens [60] including tandem epitopes against multiple pathogens on the same polypeptide [61] . Seeds are particularly valuable in this context because not only are they edible, they are also difficult to digest, which means that vaccine antigens expressed in seeds are released into the gut slowly thus increasing their ability to interact with immune effector cells (see Hofbauer and Stoger, this issue). Oral vaccines can elicit both systemic and mucosal immune responses if the antigen is protected by the plant cell matrix, and although this can also be achieved using coated formulations that dissolve slowly, the same effect can be accomplished by expressing antigens in seeds and targeting them for accumulation in protein storage compartments, particularly protein bodies in rice which are highly resistant to digestion [62] . Prophylactic oral antibodies can also be delivered in seeds, as shown by the expression in peas of anti-Eimeria spp. single chain anitbodies with high sporozoiteneutralizing activity, which can be used to prevent coccidiosis in chickens [63] . Again, a clear advantage of edible organs is the low cost of downstream processing, which in the case of oral vaccines/antibodies delivered in seeds may conceivably mean no processing at all. The delivery of HIV-neutralizing antibodies in seeds, which can then be delivered topically as crude plant extracts, is another inexpensive solution to the production of pharmaceuticals in the developing world that is being actively considered [2] .
CONCLUSION AND OUTLOOK
Molecular farming in plants has many technical and economic advantages that make it commercially attractive, but the biopharmaceutical industry has become reliant on a small number of standardized and approved platform technologies and has invested heavily in the corresponding infrastructure. The established technologies have evolved by incremental improvements and can produce yields of recombinant protein at least an order of magnitude higher than any plant-based system. Therefore, rather than seeking to displace these incumbent technologies by direct competition, molecular farming is now evolving as a disruptive technology, providing game-changing benefits in a small number of niche markets. These benefits include optimized glycans, the versatility to adapt to market forces that cannot be satisfied with the current platforms (individualized therapies, rapid-response vaccines, bulk 'commodity' antibody manufacturing) and the unique properties of cereal seeds that provide an efficient strategy for oral vaccination. As further technical developments unfold, the number of market needs that can be met by plants will increase. For example, the combination of rapid response and bioencapsulation for oral vaccines could be met by the production of vaccine antigens in tobacco plastids, as recently shown for the production of coagulation factor IX in tobacco leaves and the subsequent demonstration that orally administered tobacco leaves can prevent anaphylactic reactions in a mouse model of hemophilia B [64] . The value of incorporating quality by design (QbD) principles based on the early implementation of design of experiments (DOE) in process development has recently been shown to increase yields and batch-to-batch consistency in both transgenic and transient systems, which will help to make molecular farming even more competitive [65, 66] . The innovation demonstrated within the field of molecular farming, and the resulting versatility and adaptability, will continue to be the driving force that ensures the commercial success of this exciting and promising technology if more product candidates can be brought to the market.
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